Ken Chow1,2, Patrick McCoy1, Ryan Stuchbery3, Niall M Corcoran1,2,3, Christopher M Hovens4,5. 1. Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC, Australia. 2. Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia. 3. Australian Prostate Cancer Research Centre Epworth, Richmond, VIC, Australia. 4. Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC, Australia. chovens@unimelb.edu.au. 5. Australian Prostate Cancer Research Centre Epworth, Richmond, VIC, Australia. chovens@unimelb.edu.au.
Abstract
PURPOSE: To review the current understanding and recent developments regarding the concept of oligometastases in hormone-sensitive prostate cancer. METHODS: A comprehensive literature search of electronic databases, including PubMed and Embase was conducted for the search term 'oligometastases' in combinations with 'prostate cancer', 'hormone sensitive', 'genetics', and 'molecular'. All articles relating to these search terms have been taken into account. RESULTS: Prostate cancer remains a major cause of morbidity and mortality worldwide. The majority of these cancer-related deaths result from metastases. Currently, there is a dichotomy in prostate cancer management where it is only deemed curable if it is localized, while any signs of metastasis relegate patients to systemic therapies to delay their inevitable death. A growing body of evidence supports the notion that aggressive treatments during the stable 'oligometastatic' state can have significant clinical benefits and potentially 'reset' prostate cancer to an earlier time point in cancer progression. This concept of oligometastases has been adopted in other cancer settings such as colorectal and non-small-cell lung cancers. CONCLUSION: Multiple clinical and molecular biological studies have been influential in the support of a stable state in metastatic cancer progression coined 'oligometastases'. As our understanding of oligometastases in hormone-sensitive prostate cancer develops, we will be able to molecularly define the oligometastatic state and develop clinically available diagnostic tests. In doing so, prostate cancer patients will experience significant clinical benefits and the burden of prostate cancer worldwide will likely be reduced.
PURPOSE: To review the current understanding and recent developments regarding the concept of oligometastases in hormone-sensitive prostate cancer. METHODS: A comprehensive literature search of electronic databases, including PubMed and Embase was conducted for the search term 'oligometastases' in combinations with 'prostate cancer', 'hormone sensitive', 'genetics', and 'molecular'. All articles relating to these search terms have been taken into account. RESULTS:Prostate cancer remains a major cause of morbidity and mortality worldwide. The majority of these cancer-related deaths result from metastases. Currently, there is a dichotomy in prostate cancer management where it is only deemed curable if it is localized, while any signs of metastasis relegate patients to systemic therapies to delay their inevitable death. A growing body of evidence supports the notion that aggressive treatments during the stable 'oligometastatic' state can have significant clinical benefits and potentially 'reset' prostate cancer to an earlier time point in cancer progression. This concept of oligometastases has been adopted in other cancer settings such as colorectal and non-small-cell lung cancers. CONCLUSION: Multiple clinical and molecular biological studies have been influential in the support of a stable state in metastatic cancer progression coined 'oligometastases'. As our understanding of oligometastases in hormone-sensitive prostate cancer develops, we will be able to molecularly define the oligometastatic state and develop clinically available diagnostic tests. In doing so, prostate cancerpatients will experience significant clinical benefits and the burden of prostate cancer worldwide will likely be reduced.
Authors: U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam Journal: J Thorac Cardiovasc Surg Date: 1997-01 Impact factor: 5.209
Authors: Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal Journal: Nature Date: 2010-10-28 Impact factor: 49.962
Authors: Manav Korpal; Brian J Ell; Francesca M Buffa; Toni Ibrahim; Mario A Blanco; Toni Celià-Terrassa; Laura Mercatali; Zia Khan; Hani Goodarzi; Yuling Hua; Yong Wei; Guohong Hu; Benjamin A Garcia; Jiannis Ragoussis; Dino Amadori; Adrian L Harris; Yibin Kang Journal: Nat Med Date: 2011-08-07 Impact factor: 53.440
Authors: Yves A Lussier; Nikolai N Khodarev; Kelly Regan; Kimberly Corbin; Haiquan Li; Sabha Ganai; Sajid A Khan; Jennifer L Gnerlich; Jennifer Gnerlich; Thomas E Darga; Hanli Fan; Oleksiy Karpenko; Philip B Paty; Mitchell C Posner; Steven J Chmura; Samuel Hellman; Mark K Ferguson; Ralph R Weichselbaum Journal: PLoS One Date: 2012-12-10 Impact factor: 3.240
Authors: Yeona Cho; Jee Suk Chang; Koon Ho Rha; Sung Joon Hong; Young Deuk Choi; Won Sik Ham; Jun Won Kim; Jaeho Cho Journal: PLoS One Date: 2016-01-25 Impact factor: 3.240
Authors: Sean P Pitroda; Nikolai N Khodarev; Lei Huang; Abhineet Uppal; Sean C Wightman; Sabha Ganai; Nora Joseph; Jason Pitt; Miguel Brown; Martin Forde; Kathy Mangold; Lai Xue; Christopher Weber; Jeremy P Segal; Sabah Kadri; Melinda E Stack; Sajid Khan; Philip Paty; Karen Kaul; Jorge Andrade; Kevin P White; Mark Talamonti; Mitchell C Posner; Samuel Hellman; Ralph R Weichselbaum Journal: Nat Commun Date: 2018-05-04 Impact factor: 14.919
Authors: E M Kwan; I A Thangasamy; J Teh; O Alghazo; N J Sathianathen; N Lawrentschuk; A A Azad Journal: World J Urol Date: 2020-01-02 Impact factor: 4.226